The Wall Street Transcript
The Wall Street Transcript - In-Depth Interviews for Investors
Healthcare >> CEO Interviews >> March 22, 2019

Interview with the CEO: NeuBase Therapeutics, Inc. (NASDAQ:NBSE)

Stephan, Dietrich A.
Dietrich A. Stephan, Ph.D., is Chief Executive Officer of NeuBase Therapeutics, Inc. Before NeuBase, Dr. Stephan was CEO of LifeX. Prior, he served as Chair of the Department of Human Genetics at the University of Pittsburgh from 2013 to 2018, and earlier as the founding Chairman of the Neurogenomics Department and Deputy Director for Discovery Research at the Translational Genomics Research Institute. In these capacities, he identified many genes that predispose to disorders such as autism, exercise-induced heart attacks and sudden infant death syndrome and contributed to the understanding on a multitude of common “complex genetic” disorders such as Alzheimer's disease. These results have been published in journals such as Science, Nature Genetics, Proceedings of the National Academy of Science and The New England Journal of Medicine. Other roles he has had include being founder, co-founder or director of biotechnology companies, including co-founding Navigenics, a personal genetics company, Founder of DiaVacs, an immunotherapy company, and founding Chairman of the board of Whole Biome, a microbiome therapeutics company. Also, he has been an adviser to companies, including Genia Technologies and Guardant Health. Dr. Stephan has served as the Chairman of the National Institutes of Health — NIH — Neuroscience Microarray Consortium and has held faculty appointments at Johns Hopkins University, the University of Arizona and the Children's National Medical Center of George Washington University in Washington, D.C. Dr. Stephan received his B.S. at Carnegie-Mellon University, his Ph.D. at the University of Pittsburgh and trained as a fellow at the National Human Genome Research Institute of the NIH. Profile
Word count: 3,172

TWST: You founded NeuBase Therapeutics. Tell us why and a little about the company.

Dr. Stephan: NeuBase is a therapeutics company that is

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Walmart Inc.
International Business Machines Corporation
Citigroup Inc.
Exxon Mobil Corporation
Bank of America Corporation
Dell Inc.
Verizon Communications Inc.
Alphabet Inc

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS
Interview with the CEO: Pasithea Therapeutics Corp. (NASDAQ:KTTA)
Interview with the CEO: BetterLife Pharma Inc. (OTCMKTS:BETRF)
Interview with the CEO: Cansortium Inc. (OTCMKTS:CNTMF)
SECTOR ROUNDTABLES
Natural Gas Weighs Heavy On E&P Near-Term Prospects
Roundtable Forum:optimism Despite Uncertainty In For-profit Education
Roundtable Forum:a Shift In Focus To Natural Gas From Oil
MONEY MANAGER INTERVIEWS
AI Opportunities Expand to Industrial, Utilities and Energy Sectors
India Fund Manager Expects Discretionary Spending to Grow
Inefficiency in Ex-US Markets Creates Opportunity to Buy at a Discount
ANALYST INTERVIEWS
Five Companies Dominate in Psychedelics-Based Drug Development
Cidara’s Long-Acting Antiviral Drug Could Be a Game Changer
Spotting Potential in the High-Risk, High Reward Neuroscience Space
Since 1963
© The Wall Street Transcript 2016, 2024
Terms and Conditions
Privacy Policy